Linked Life Data

12174342

Source:http://linkedlifedata.com/resource/pubmed/id/12174342

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3 Suppl 2
pubmed:dateCreated
2002-8-13
pubmed:abstractText
Activation of Ras, by mutation, overexpression, or by signaling through tyrosine kinase receptors, is associated with radioresistance. Thus, therapies that inhibit Ras function could be an effective means to radiosensitize selected types of solid tumors. Inhibition of Ras prenylation using a variety of farnesyltransferase inhibitors resulted in radiosensitization of tumor cells that expressed activated Ras, both in vitro and in xenograft models. Farnesyltransferase inhibitor treatment could also inhibit tumor regrowth following irradiation of mice bearing T24 tumor xenografts that express activated Ras. In a phase I trial of the farnesyltransferase inhibitor L-778-123 and radiotherapy in patients with locally advanced head and neck cancer and non-small cell lung cancer, a high response rate was observed coupled with a mild toxicity profile. Additional clinical trials should shed light on the potential of this and other farnesyltransferase inhibitors to serve as radiosensitizers and may identify molecular markers that could predict a response to these agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1053-4296
pubmed:author
pubmed:copyrightInfo
Copyright 2002, Elsevier Science (USA). All rights reserved.
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-32
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Farnesyltransferase inhibitors as radiation sensitizers.
pubmed:affiliation
Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104, USA.
pubmed:publicationType
Journal Article, Review